MEG3 (Gene)

Omim:OMIM:605636

Id:fddaf084-1d73-5b32-ae62-28012a9e7231

Hgnc:HGNC:14575

Entrez:55384

Description:maternally expressed 3

This gene is a maternally expressed imprinted gene. Multiple alternatively spliced transcript variants have been transcribed from this gene and all of them are long non-coding RNAs (lncRNAs). This gene is expressed in many normal tissues, but its expression is lost in multiple cancer cell lines of various tissue origins. It inhibits tumor cell proliferation in vitro. It also interacts with the tumor suppressor p53, and regulates p53 target gene expression. Its deletion enhances angiogenesis in vivo. Many experimental evidences demonstrate that this gene is a lncRNA tumor suppressor. [provided by RefSeq, Mar 2012]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View MEG3's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with MEG3.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using MEG3.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for MEG3.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with MEG3.

Results found

Linked to

	Label	Description
	GSE156648 DOT1L overexpression IMR-90 2 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE156648 DOT1L overexpression IMR-90 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE74251 decitabine MCF-7 2 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE108464 AZ-628 6 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 13 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 15 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE214505 AKR1B1 knockdown A-549 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 saha 8 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE137325 copanlisib Hair-M 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 nicotinamide 5 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE156648 DOT1L overexpression IMR-90 2 v 3 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE156648 DOT1L overexpression IMR-90 2 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE74251 decitabine MCF-7 2 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE108464 AZ-628 6 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 13 v 5 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 15 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE214505 AKR1B1 knockdown A-549 3 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE77108 saha 8 v 9 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE137325 copanlisib Hair-M 2 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE233679 nicotinamide 5 v 9 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.